## Vijayaraj K Palanirajan

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7721704/publications.pdf

Version: 2024-02-01

49 papers

1,727 citations

471371 17 h-index 276775 41 g-index

52 all docs 52 docs citations

times ranked

52

2245 citing authors

#	Article	IF	CITATIONS
1	Dendrimers in Oncology: An Expanding Horizon. Chemical Reviews, 2009, 109, 49-87.	23.0	446
2	Intracellular macrophage uptake of rifampicin loaded mannosylated dendrimers. Journal of Drug Targeting, 2006, 14, 546-556.	2.1	194
3	Dendrimers as therapeutic agents: a systematic review. Journal of Pharmacy and Pharmacology, 2010, 61, 989-1003.	1.2	148
4	Functional Polymeric Nanoparticles: An Efficient and Promising Tool for Active Delivery of Bioactives. Critical Reviews in Therapeutic Drug Carrier Systems, 2006, 23, 259-318.	1.2	140
5	Pharmaceutical and Biomedical Potential of PEGylated Dendrimers. Current Pharmaceutical Design, 2007, 13, 415-429.	0.9	119
6	PEGylated PPI dendritic architectures for sustained delivery of H2 receptor antagonist. European Journal of Medicinal Chemistry, 2009, 44, 1155-1166.	2.6	87
7	Dendrimers as therapeutic agents: a systematic review. Journal of Pharmacy and Pharmacology, 2009, 61, 989-1003.	1.2	68
8	PEGylated Dendritic Architecture for Development of a Prolonged Drug Delivery System for an Antitubercular Drug. Current Drug Delivery, 2007, 4, 11-19.	0.8	64
9	Microwave-assisted synthesis, characterization and biological activity of novel pyrazole derivatives. Journal of Saudi Chemical Society, 2014, 18, 1015-1021.	2.4	34
10	Formulation and evaluation of voriconazole ophthalmic solid lipid nanoparticles in situ gel. International Journal of Pharmaceutical Investigation, 2016, 6, 56.	0.2	34
11	Novel PEGylated PPI Dendritic Nanostructures for Sustained Delivery of Anti-Inflammatory Agent. Current Nanoscience, 2008, 4, 267-277.	0.7	33
12	Dendrimeric nanoarchitectures mediated transdermal and oral delivery of bioactives. Indian Journal of Pharmaceutical Sciences, 2008, 70, 431.	1.0	32
13	Evaluation of Antidiarrheal Potential of Emblica officinalis Pharmaceutical Biology, 2005, 43, 373-377.	1.3	30
14	Dendrosome-based gene delivery. Journal of Experimental Nanoscience, 2006, 1, 235-248.	1.3	30
15	Suppression of agglomeration of ciprofloxacin-loaded human serum albumin nanoparticles. AAPS PharmSciTech, 2007, 8, E118-E123.	1.5	28
16	Polyethylene glycolated PAMAM dendrimers-Efavirenz conjugates. International Journal of Pharmaceutical Investigation, 2014, 4, 15.	0.2	20
17	RP-HPLC determination of vildagliptin in pure andÂin tablet formulation. Journal of Pharmacy Research, 2013, 7, 113-116.	0.4	17
18	Fabrication and Evaluation of Transdermal Microneedles for a Recombinant Human Keratinocyte Growth Factor. Turkish Journal of Pharmaceutical Sciences, 2021, 18, 96-103.	0.6	11

#	Article	IF	CITATIONS
19	A New Approach for $\hat{l}^2$ -cyclodextrin Conjugated Drug Delivery System in Cancer Therapy. Current Drug Delivery, 2022, 19, 266-300.	0.8	11
20	Design, synthesis, antinociceptive, and anti-inflammatory properties of thiazolopyrimidine derivatives. Toxicological and Environmental Chemistry, 2012, 94, 1247-1258.	0.6	10
21	Enhanced gastrointestinal survivability of recombinant Lactococcus lactis using a double coated mucoadhesive film approach. PLoS ONE, 2019, 14, e0219912.	1.1	10
22	Molecular Modeling- <sub>B</sub> ased Delivery System Enhances Everolimus-Induced Apoptosis in Caco-2 Cells. ACS Omega, 2019, 4, 8767-8777.	1.6	10
23	Regulatory mechanisms of heme regulatory protein BACH1: a potential therapeutic target for cancer. Medical Oncology, 2021, 38, 122.	1.2	10
24	Synthesis and structure-activity relationship study of 2-(substituted) Tj ETQq $000$ rgBT /Overlock $10$ Tf $50$ 547 Td anticancer agents. Drug Discoveries and Therapeutics, $2012$ , , .	(benzylide 0.6	ene)-7-(4-flu 8
25	Formulation of Rifampicin Loaded PEGylated 5.0G EDA-PAMAM Dendrimers as Effective Long-Duration Release Drug Carriers. Current Drug Therapy, 2017, 12, .	0.2	8
26	Revolution in the Synthesis, Physio-chemical and Biological Characterization of Gold Nanoplatform. Current Pharmaceutical Design, 2021, 27, 2482-2504.	0.9	7
27	Designing and In-Vitro Characterization of Micelle Forming Amphiphilic PEGylated Rapamycin Nanocarriers for the Treatment of Gastric Cancer. Current Drug Delivery, 2014, 11, 613-620.	0.8	6
28	Synthesis and anticonvulsant activity of 6,7,8,9-tetra hydro-5H-5-(2′-hydroxy phenyl)-2-(4′-substituted) Tj ETenvironmental Chemistry, 2011, 93, 643-655.	Qq0 0 0 rg 0.6	gBT /Overloo 5
29	Cyclodextrin inclusion complex inhibits circulating galectin-3 and FGF-7 and affects the reproductive integrity and mobility of Caco-2 cells. Scientific Reports, 2020, 10, 17468.	1.6	5
30	Mucoadhesive Low Molecular Chitosan Complexes to Protect rHuKGF from Proteolysis: In-vitro Characterization and FHs 74 Int Cell Proliferation Studies. Current Pharmaceutical Biotechnology, 2021, 22, 969-982.	0.9	5
31	Detection of Formation of Recombinant Human Keratinocyte Growth Factor Loaded Chitosan Nanoparticles Based on its Optical Properties. Current Nanoscience, 2018, 14, 127-135.	0.7	5
32	Synthesis of Novel 6,7,8,9-Tetrahydro-5H-5-hydroxyphenyl-2-benzylidine-3-substituted Hydrazino Thiazolo (2,3-b) Quinazoline as Potent Antinociceptive and Anti-inflammatory Agents. Bulletin of the Korean Chemical Society, 2010, 31, 3265-3271.	1.0	5
33	Synthesis, characterization, and antihyperglycemic activity of novel oxazolidine derivatives. Archives of Pharmacal Research, 2011, 34, 887-891.	2.7	4
34	Recent Advances in Physical Approaches for Transdermal Penetration Enhancement. Current Drug Therapy, 2012, 7, 184-197.	0.2	4
35	Rabbit as an Animal Model for Pharmacokinetics Studies of Enteric Capsule Contains Recombinant Human Keratinocyte Growth Factor Loaded Chitosan Nanoparticles. Current Clinical Pharmacology, 2019, 14, 132-140.	0.2	4
36	Preparation of Chitosan Particles as a Delivery System for Tetrahydrocurcumin: β-cyclodextrin Inclusive Compound for Colorectal Carcinoma. Current Drug Therapy, 2021, 16, 430-438.	0.2	4

#	Article	IF	CITATIONS
37	UV Spectrophotometric Method for Determination of Cinitapride in Pure and its Solid Dosage Form. E-Journal of Chemistry, 2009, 6, S21-S24.	0.4	3
38	Synthesis and cAMP-dependent phosphodiesterase inhibition of novel thiazoloquinazoline derivatives. Acta Pharmaceutica, 2011, 61, 103-13.	0.9	3
39	PEGylated dendritic nanoarchitechture improves mean survival time of BDF1 mice bearing myelogenous k -562 leukemia. Journal of Acute Disease, 2013, 2, 327-329.	0.0	2
40	Preparation and In vitro Evaluation of Enteric Coated Oral Vancomycin Hydrochloride Sustained Release Formulation with Mucoadhesive Properties. American Journal of Advanced Drug Delivery, 2018, 06, .	0.1	2
41	New Generation Peptide-Based Vaccine Prototype. , 0, , .		2
42	UV Spectrophotometric Estimation of Acipimox inBulk and Capsule Dosage Form. E-Journal of Chemistry, 2009, 6, 1117-1120.	0.4	1
43	Antiepileptic Activity of Novel 2-(substituted benzylidene)-7-(4-) Tj ETQq1 1 0.784314 rgBT /Overlock 10 Tf 50 50 and Discovery, 2013, 10, 204-211.	07 Td (fluc 0.4	orophenyl)-5 1
44	Antiepileptic properties of novel 2-(substituted benzylidene)-7-(4-chlorophenyl)-5-(furan-2-yl)-2 H -thiazolo[3,2 -a]pyrimidin-3(7 H)-one derivatives. Journal of Saudi Chemical Society, 2016, 20, S1-S6.	2.4	1
45	In silico-based Approach to Investigate the Ability of PEGylated Rapamycin to Inhibit Galectin-3. Current Drug Discovery Technologies, 2021, 18, 451-456.	0.6	1
46	Ultrathin multilayer capsules in drug delivery. Indian Journal of Pharmaceutical Sciences, 2007, 69, 479.	1.0	1
47	Antiepileptic Activity of Novel 2-(substituted benzylidene)-7-(4-) Tj ETQq1 1 0.784314 rgBT /Overlock 10 Tf 50 34 and Discovery, 2013, 10, 204-211.	47 Td (fluc 0.4	orophenyl)-5 1
48	RP-HPLC method for the determination of acipimox in human plasma. Journal of Pharmacy Research, 2013, 7, 117-120.	0.4	0
49	Optimization and <i>In-vitro</i> Evaluation of Coating Process for Film-Coated Tablets. International Journal of Food Engineering, 2017, 13, .	0.7	O